PerpEquitiesEquity
SMMT perpetual futures
Summit Therapeutics Inc. tracked across crypto venues with normalized contract specs.
Price chart
15.56▲ 0.10%
15.4815.5015.5215.5415.56
01:37 PM02:18 PM03:00 PM03:41 PM04:22 PM
24/7 perp mark · BingX (SMMT-USDT)
Auto: market closed → highest-volume perp venue
Trading data
Perpetual market activity
Venues
1
Live markets
1/1
24h volume
$169k
Open interest
$224
Best liquidity
$10k
BingX
Tightest spread
+12.7 bps
BingX
Highest volume
$169k
BingX
Settlement mix
USDT · 1/1
Best Liquidity
SMMTTightest Spread
SMMTHighest Volume
SMMTCompany data
Company fundamentals
Market cap
$12.1B
Updated 3h ago
Revenue
$0.0
Trailing 12 months
Net income
$-1.1B
Trailing 12 months
Free cash flow
$-286.9M
Trailing 12 months
Profit margin
0.0%
P/E
-11.1
P/S
-
Revenue estimate
$3.2M
Next fiscal year
Revenue growth
-
Next fiscal year
Fundamental detail
Annual + quarterlyLatest revenue$0.0
Net margin+0.0%
Free cash flow$-240.2M
Net debt$-151.7M
PeriodRevenueGrowthNet incomeFCF
2020$629k-23%$-38.5M$-35.6M
2021$1.3M+113%$-65.5M$-54.0M
2022$583k-56%$-65.2M$-34.4M
2023$0.0-100%$-482.4M$-60.8M
2024$0.0-$-176.8M$-113.7M
2025$0.0-$-1.1B$-240.2M
PeriodGross marginOperating marginNet marginROEROA
2020+100.0%-11392.7%-6127.6%-66.0%-51.2%
2021+100.0%-4764.3%-4897.8%-106.1%-78.0%
2022+100.0%-10225.4%-11174.8%-63.1%-12.0%
2023+0.0%+0.0%+0.0%-784.6%-300.3%
2024+0.0%+0.0%+0.0%-56.9%-50.8%
2025+0.0%+0.0%+0.0%-220.8%-193.6%
PeriodCashDebtNet debtCurrent ratio
2020$48.8M$342k$-48.4M4.41
2021$53.2M$2.1M$-51.2M3.80
2022$284.2M$422.9M$138.7M16.93
2023$56.5M$84.0M$27.4M9.30
2024$83.8M$5.8M$-78.0M10.15
2025$167.2M$15.5M$-151.7M9.87
PeriodMarket capEnterprise valueP/SP/E
2020$325.9M$277.4M518.2-8.5
2021$248.1M$197.0M185.5-3.8
2022$816.6M$955.4M1400.3-12.5
2023$1.6B$1.6B0.0-3.3
2024$12.7B$12.7B0.0-71.4
2025$13.1B$12.9B0.0-12.1
PeriodRevenueGrowthNet incomeFCF
Q2 2024$0.0-$-47.8M$-26.1M
Q3 2024$0.0-$-42.1M$-23.2M
Q4 2024$0.0-$-48.9M$-38.9M
Q1 2025$0.0-$-48.7M$-47.7M
Q2 2025$0.0-$-412.2M$-49.0M
Q3 2025$0.0-$-231.8M$-69.2M
Q4 2025$0.0-$-219.2M$-75.8M
Q1 2026$0.0-$-189.4M$-92.9M
PeriodGross marginOperating marginNet marginROEROA
Q2 2024+0.0%+0.0%+0.0%-31.0%-17.7%
Q3 2024+0.0%+0.0%+0.0%-12.6%-11.0%
Q4 2024+0.0%+0.0%+0.0%-15.7%-14.0%
Q1 2025+0.0%+0.0%+0.0%-18.3%-16.4%
Q2 2025+0.0%+0.0%+0.0%-216.5%-173.3%
Q3 2025+0.0%+0.0%+0.0%-162.2%-119.1%
Q4 2025+0.0%+0.0%+0.0%-44.8%-39.3%
Q1 2026+0.0%+0.0%+0.0%-45.8%-38.6%
PeriodCashDebtNet debtCurrent ratio
Q2 2024$22.5M$85.9M$63.4M2.35
Q3 2024$71.5M$24.8M$-46.7M8.31
Q4 2024$83.8M$5.8M$-78.0M10.15
Q1 2025$163.8M$5.0M$-158.8M10.63
Q2 2025$218.6M$4.1M$-214.5M5.13
Q3 2025$177.3M$4.0M$-173.3M3.80
Q4 2025$167.2M$15.5M$-151.7M9.87
Q1 2026$80.8M$15.2M$-65.6M7.41
PeriodMarket capEnterprise valueP/SP/E
Q2 2024$5.5B$5.5B0.0-30.1
Q3 2024$15.4B$15.4B0.0-94.6
Q4 2024$12.2B$12.1B0.0-67.3
Q1 2025$13.5B$13.3B0.0-73.1
Q2 2025$15.8B$15.6B0.0-9.5
Q3 2025$15.4B$15.2B0.0-16.7
Q4 2025$13.4B$13.3B0.0-15.1
Q1 2026$14.7B$14.6B0.0-19.8
Refreshed 3h ago
Research data
Estimates, events and peers
Estimates
6 periodsFY 2026$3.2M-10 analysts
FY 2027$76.1M-10 analysts
FY 2028$731.7M-12 analysts
FY 2029$2.0B-11 analysts
FY 2030$3.9B-6 analysts
Q2 2026$109k-12 analysts
Events
Earnings · dividends · splits2026-08-10EarningsRevenue est. $109k
2026-04-30EarningsRevenue est. $54k
2026-02-23EarningsRevenue est. $56.8M
2025-10-20EarningsRevenue est. $76.5M
2025-08-11EarningsEPS est. -0.09081
2025-05-01EarningsEPS est. -0.09302